Pretreatment minimal staging and prognostic factors for non-small cell lung cancer.

Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax (2001) 2.24

Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. Ann Surg (2003) 1.33

Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol (2014) 0.92

Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol (2012) 0.89

Absence of a relationship between tumor ¹⁸F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer. J Thorac Oncol (2014) 0.81

Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA (1998) 10.09

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08

Culture-independent diagnosis of Chlamydia trachomatis using monoclonal antibodies. N Engl J Med (1984) 6.08

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer (2007) 4.44

Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck (2005) 4.27

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol (2000) 3.69

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40

The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg (2001) 3.24

Psychosocial correlates of oestrogen and progesterone receptors in breast cancer. Lancet (1990) 3.14

Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J (2001) 3.04

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol (2002) 3.03

Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1999) 2.86

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst (2000) 2.56

Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer (2000) 2.51

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer (1998) 2.27

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J (2009) 2.21

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis (2001) 2.03

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.99

Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest (1999) 1.99

Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96

The impact of providing incentives for attendance at AIDS prevention sessions. Public Health Rep (1994) 1.95

A neurovisceral storage disease with vertical supranuclear ophthalmoplegia, and its relationship to Niemann-Pick disease. A report of nine patients. Brain (1973) 1.94

The truthfulness of addict respondents in research projects. Int J Addict (1972) 1.94

Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol (2006) 1.92

Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer (2005) 1.92

CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood (1997) 1.89

Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer (2008) 1.88

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 1.85

Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med (1992) 1.83

Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis (1999) 1.81

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer (2004) 1.79

The cancer burden in Africa. S Afr Med J (2007) 1.79

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2009) 1.75

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol (2011) 1.73

A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat (2001) 1.72

Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med (2000) 1.69

A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol (1997) 1.63

Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer (2000) 1.61

Smoking and occupational allergy in workers in a platinum refinery. BMJ (1989) 1.60

IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res (2009) 1.60

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J (2002) 1.57

Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents (2007) 1.57

Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann Oncol (2003) 1.56

Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2003) 1.54

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2002) 1.52

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer (2004) 1.52

Histological alterations in chronically hypoperfused myocardium. Correlation with PET findings. Circulation (1994) 1.52

Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N Engl J Med (1987) 1.49

CD3+CD8+ cell levels as predictors of transmission in human immunodeficiency virus-infected couples: a report from the heterosexual HIV transmission study. Int J Infect Dis (1998) 1.48

Abnormalities on neurological examination among sheep farmers exposed to organophosphorous pesticides. Occup Environ Med (1996) 1.44

Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer (2001) 1.44

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer (2006) 1.41

Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ (2003) 1.41

A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol (1999) 1.40

Safety and cost effectiveness of high-osmolality as compared with low-osmolality contrast material in patients undergoing cardiac angiography. N Engl J Med (1992) 1.40

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs (1990) 1.40

Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer (2002) 1.40

[EGF-R expression correlation between biopsy and surgical specimens of lung carcinoma]. Rev Mal Respir (2003) 1.39

[Pathologic diagnosis of mediastinal lymph nodes]. Rev Mal Respir (2003) 1.39

Guidelines on the use of space maintainers. J Can Dent Assoc (1998) 1.39

[Endobronchial ultrasound and PET positive mediastinal lymph nodes]. Rev Mal Respir (2006) 1.38

Statement on withholding and withdrawing life-sustaining therapy. S Afr Med J (1994) 1.38

Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys (1980) 1.38

Mitomycin, ifosfamide, cisplatin for non-small cell lung cancer: an implementation study. Monaldi Arch Chest Dis (2005) 1.38

The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38

Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37

Longevity of the immune response and memory to blood-stage malaria infection. Curr Top Microbiol Immunol (2005) 1.36

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2005) 1.36

A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides. Curr Biol (1995) 1.35

Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J (2008) 1.35

School-associated violent deaths in the United States, 1992 to 1994. JAMA (1996) 1.34

High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res (1999) 1.32

Quality of life assessment in clinical trials--guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office. Eur J Cancer (1997) 1.32

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31

Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol (1998) 1.31

Malaria-specific antibody responses and parasite persistence after infection of mice with Plasmodium chabaudi chabaudi. Parasite Immunol (2007) 1.31

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer (2000) 1.27

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol (2001) 1.26

A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer (2000) 1.26

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol (2011) 1.24

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer (2012) 1.24

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol (2001) 1.23

Recommendations for a Global Core Curriculum in Medical Oncology. Ann Oncol (2004) 1.22

Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res (1974) 1.22

Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. Eur J Biochem (1982) 1.21

Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur Respir J (1999) 1.20

Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem (1989) 1.20

Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer (2007) 1.20

Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol (2011) 1.19

Late onset GM2-gangliosidosis. Clinical, pathological, and biochemical studies on 8 patients. Arch Dis Child (1973) 1.19

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother (1996) 1.19

Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg (2001) 1.19

The effects of a 24-h psychological training program on attitudes, communication skills and occupational stress in oncology: a randomised study. Eur J Cancer (1993) 1.18

Identification of residues that control specific binding of the Shc phosphotyrosine-binding domain to phosphotyrosine sites. Proc Natl Acad Sci U S A (1996) 1.18

Decomposition of T6 bacteriophage in alkaline solutions. Virology (1964) 1.17

Syndrome of the sea-blue histiocyte. Lancet (1970) 1.16